Revolution raises $100M to build out Ras pipeline, explore SHP-2 combos

How Revolution Medicines plans to deploy Boxer Capital-led series C to advance portfolio of Ras pathway inhibitors

Following this year’s ASCO fervor around KRAS inhibitors, Revolution Medicines has raised $100 million in a series C round to advance its portfolio of Ras pathway inhibitors, including its own KRAS G12C inhibitor.

The financing, announced Tuesday, was led by Boxer Capital of the Tavistock Group. Also participating were Cormorant Capital, Deerfield Management, Fidelity Management & Research Co., Vivo Capital and Biotechnology Value Fund, as well as all series B investors, including Nextech Invest, Schroder Adveq, The

Read the full 769 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE